Rubius Therapeutics Inc (RUBY)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Dannielle Appelhans
Employees:
6
325 VASSAR STREET, SUITE 1A, CAMBRIDGE, MA 02139
617-679-9600

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the. treatment of solid tumors cancer. It is also developing. RTX-321 for the the treatment. of HPV-positive tumors;. and RTX-T1D for treating type 1 diabetes.

Data derived from most recent annual or quarterly report
Market Cap 7.51 Million Shares Outstanding90.483 Million Avg 30-day Volume 8.994 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.99
Price to Revenue0.0 Debt to Equity0.0 EBITDA-170.673 Million
Price to Book Value1.0444 Operating Margin0.0 Enterprise Value938.456 Thousand
Current Ratio2.544 EPS Growth0.108 Quick Ratio1.872
1 Yr BETA 1.3796 52-week High/Low 6.18 / 0.08 Profit Margin0.0
Operating Cash Flow Growth-3.4592 Free Cash Flow to Firm (FCFF) TTM -92.02 Million Free Cash Flow to Equity (FCFE) TTM-112.273 Million
Altman Z-Score-75.4204
View SEC Filings from RUBY instead.

View recent insider trading info

Rubius Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding RUBY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RUBY

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-27 by APPELHANS DANNIELLE
  • 4: filed on 2022-08-12 by APPELHANS DANNIELLE
  • 4: filed on 2022-08-01 by SCHAFFERT SUSANNE
  • 3: filed on 2022-07-19 by SCHAFFERT SUSANNE
  • 4: filed on 2022-05-13 by PRENER ANNE
  • 4: filed on 2022-05-13 by HOLLES NATALIE C.
  • 4: filed on 2022-05-13 by CUSS FRANCIS M
  • 4: filed on 2022-05-13 by ROSENBLATT MICHAEL
  • 4: filed on 2022-05-13 by SOHN CATHERINE A.
  • 4: filed on 2022-05-13 by AFEYAN NOUBAR

    • Events (8k)

  • 8-K: filed on 2023-04-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-03:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-06:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-12-21:
    Item 2.01: Completion of Acquisition or Disposition of Assets
  • 8-K: filed on 2022-12-14:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-02:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-10-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-10-13:
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    APPELHANS DANNIELLE CEO AND PRESIDENT

    • Officer
    		 0 2023-02-24 2

    CAGNONI PABLO J

    • Director
    		 66,082 2023-02-01 2

    TURKA LAURENCE A. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 71,499 2023-01-29 1

    SCHAFFERT SUSANNE

    • Director
    		 50,000 2022-07-29 0

    AFEYAN NOUBAR

    • Director
    • 10% Owner
    		 25,000 2022-05-12 0

    EPSTEIN DAVID R

    • Director
    		 499,762 2022-05-12 0

    ROSENBLATT MICHAEL

    • Director
    		 25,000 2022-05-12 0

    CUSS FRANCIS M

    • Director
    		 25,000 2022-05-12 0

    SOHN CATHERINE A.

    • Director
    		 25,000 2022-05-12 0

    HOLLES NATALIE C.

    • Director
    		 25,000 2022-05-12 0

    SYMONDS JONATHAN

    • Director
    		 25,000 2022-05-12 0

    PRENER ANNE

    • Director
    		 25,000 2022-05-12 0

    CARMONA JOSE CHIEF FINANCIAL OFFICER

    • Officer
    		 178,250 2022-01-31 0

    KESON-BROOKES MAIKEN CLO & CORP. SECRETARY

    • Officer
    		 215,893 2022-01-29 0

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP VENTURES OPPORTUNITIES FUND I GENERAL PARTNER LLC

    FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

    AFEYAN NOUBAR

    • Director
    • 10% Owner
    		 38,506,526 2021-03-19 0

    COUGHLIN CHRISTINA M. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2021-01-29 0

    OH ANDREW M. CHIEF FINANCIAL OFFICER

    • Officer
    		 5,000 2020-05-15 0

    CARPENTER CHRISTOPHER L. CHIEF MEDICAL OFFICER

    • Officer
    		 34,843 2019-12-16 0

    LANGER ROBERT

    • Director
    		 0 2019-10-14 0

    NISSEN TORBEN STRAIGHT PRESIDENT

    • Officer
    		 No longer subject to file 2019-07-24 0

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    FLAGSHIP VENTURELABS IV, LLC

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND IV-RX, L.P.

    FLAGSHIP VENTURES FUND V, L.P.

    FLAGSHIP V VENTURELABS RX FUND, L.P.

    FLAGSHIP VENTURES OPPORTUNITIES FUND I, L.P.

    AFEYAN NOUBAR

    KANIA EDWIN M JR

    • Director
    • 10% Owner
    		 56,266,265 2018-07-20 0

    POMERANTZ ROGER

    • Director
    		 100 2018-07-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 22:15:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 21:45:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 21:15:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 20:45:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 20:15:07 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 19:45:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 19:15:03 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 18:45:03 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 18:15:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 17:45:03 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 17:15:03 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 16:45:05 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 16:15:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 15:45:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 15:15:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 14:45:04 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 14:15:03 UTC -15.7911 21.1111 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 13:45:03 UTC -15.7879 21.1079 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 13:15:04 UTC -15.7879 21.1079 1200000
    RUBIUS THERAPEUTICS INC RUBY 2023-12-08 12:45:05 UTC -15.7879 21.1079 1200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund RUBY -267.0 shares, $-1188.15 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund RUBY -1.0 shares, $-4.45 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund RUBY -203.0 shares, $-903.35 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments